Last updated: February 20, 2026
What is NDC 60505-4769?
NDC 60505-4769 corresponds to a specific drug product within the National Drug Code system. Based on available data, this code identifies Glycopyrrolate Injection, 0.2 mg/mL.
Market Overview
Glycopyrrolate Injection is a muscarinic antagonist used primarily to reduce airway secretions preoperatively and in anesthesia, as well as in certain gastrointestinal conditions. It competes with other anticholinergics for use in perioperative care, with a primary market in hospital settings.
Market Size
- The global anesthetic and perioperative drug market valued at approximately USD 9.2 billion in 2022.
- The anticholinergic segment, which includes glycopyrrolate, accounts for roughly 12% of this segment.
- The drug’s primary revenue comes from hospital and specialty clinics in the United States, with expansion into Europe and Asia.
Market Drivers
- Increased prevalence of surgeries requiring anesthesia.
- Growing demand for perioperative medications with fewer side effects.
- Aging population leading to more complex surgeries.
- Potential shortages of alternative anticholinergic drugs influencing market share.
Competition
Main competitors include:
| Drug Name |
Manufacturer |
Price (per unit) |
Market share (est.) |
| Robinul (glycopyrrolate) |
Merck & Co. |
$2.50 per 20 mL |
70% |
| Atropine Sulfate |
Various |
$1.80 per 10 mL |
20% |
| Ipratropium Bromide |
Various |
$2.20 per 20 mL |
10% |
Generic availability and hospital purchasing agreements influence market share and pricing dynamics.
Price Projections
Current Pricing
- Wholesale acquisition cost (WAC): Roughly USD 2.50 per 20 mL vial.
- Average sales price (ASP): Slightly higher, around USD 3.20 per vial.
- Average reimbursement rates for hospitals are approximately USD 4.00 per vial, considering markup and insurance adjustments.
Future Price Trends (Next 3 Years)
| Year |
Projected WAC |
Projected ASP |
Key Factors |
| 2023 |
$2.55 |
$3.25 |
Stable with minor inflation |
| 2024 |
$2.60 |
$3.40 |
Potential supply constraints |
| 2025 |
$2.75 |
$3.60 |
Increased hospital demand, pricing pressures |
Price Influences
- Manufacturing costs: Inflating due to raw material prices.
- Regulatory environment: Changes imposing stricter manufacturing standards could increase costs.
- Market competition: Entry of generics is expected to reduce prices, impacting branded product prices.
- Supply chain stability: Potential disruptions could temporarily elevate prices.
Price Sensitivity
Hospital procurement policies, insurance reimbursements, and hospital tender processes make actual transaction prices variable and often below WAC or ASP estimates.
Regulatory and Patent Considerations
- Glycopyrrolate injection has been marketed since the 1980s.
- Patent protections in the U.S. expired in the mid-2000s, allowing generics.
- No current patent challenges are publicly announced, but patent exclusivity dynamics continue influencing the market.
Market Entry Barriers
- Complex manufacturing process for parenteral drugs.
- Stringent regulatory requirements.
- Existing entrenched hospital procurement contracts with major GSK and Sandoz brands.
Strategic Implications
- Companies should monitor generic entrants, as projected price reductions could shrink profit margins.
- Market expansion opportunities exist in emerging markets with increasing surgical procedures.
- R&D investments could focus on formulation improvements or new indications to extend lifecycle.
Key Takeaways
- NDC 60505-4769 identifiable as glycopyrrolate injection.
- Market dominated by hospital and surgical demand, with potential growth in emerging markets.
- Current prices hover around $3.20 to $4.00 per vial in the U.S.
- Prices are expected to stay relatively stable through 2025, with slight increases driven by supply chain and inflationary pressures.
- Competitive landscape includes generic entrants that will pressure prices downward.
FAQs
What factors most influence the price of glycopyrrolate injection?
Manufacturing costs, supply chain stability, competition from generics, and hospital procurement policies.
How does generic entry affect market prices?
Generic competition typically reduces prices; in this case, prices are projected to decline as generics gain market share.
Are there significant patent protections remaining?
No, patents expired in the mid-2000s; market dynamics now rely heavily on generics and supply chain factors.
What regions present growth opportunities?
Emerging markets in Asia and Latin America exhibit increasing surgical volumes and adoption of parenteral drugs.
What is the forecasted impact of regulation on prices?
Stricter manufacturing standards may increase costs temporarily, but long-term effects on prices are uncertain.
References
[1] SME Reports. (2022). Global anesthetic drug market analysis.
[2] IQVIA. (2023). Hospital drug purchase trends and pricing.
[3] U.S. Food and Drug Administration. (2022). Patent and exclusivity data for glycopyrrolate.
